Literature DB >> 18422804

A new technique for transumbilical insertion of central venous silicone catheters in newborn infants.

D Haumont1, V Gouder de Beauregard, I Van Herreweghe, G Delanghe, R Ciardelli, E Haelterman.   

Abstract

AIM: A new technique allowing placement of umbilical silicone venous catheters (USVC) is described and compared with percutaneous silicone venous catheters (PSVC).
METHODS: Data were retrospectively recorded for 198 infants with USVC and 141 infants with PSVC.
RESULTS: Overall rate of complications was low and comparable in both groups: thrombosis 1.2%, catheter-related sepsis 3.5% and mechanical obstruction 5%.
CONCLUSION: A new device allows safe introduction of silicone catheters into the umbilical vein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422804      PMCID: PMC2440482          DOI: 10.1111/j.1651-2227.2008.00786.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


The percutaneous silicone venous catheter (PSVC) is the preferred small-diameter central venous access in preterm infants (1). The umbilical vein is also a commonly used and easily accessible central venous route. However, because of a significant incidence of thrombosis, the polyurethane or polyvinyl chloride umbilical catheters are not suitable for long-term use (2,3). Silicone catheters lack stiffness for direct umbilical insertion. Therefore, we designed a new device for the introduction of the silicone catheter into the umbilical vein. The concept is shown in Figure 1 (ref.2184.01, Vygon). A rigid introducer serves as guide for advancing the silicone catheter into the umbilical vein. The umbilical silicone venous catheter (USVC) is inserted under classical conditions of sterile umbilical catheterisation. The silicone catheter and the easy-lock connection system are flushed with saline. One of the three introducers is chosen according to the required catheter insertion distance and flushed with saline too. The silicone catheter is inserted and pushed forward into the introducer 1–2 mm ahead of its distal end. A haemostat forceps is gently clamped at the proximal end of the introducer and will stop the catheter from moving. The introducer with the silicone catheter in his lumen is now inserted and advanced into the umbilical vein. The haemostat forceps is removed. After the introducer is advanced the appropriate distance, the silicone catheter is disconnected from the easy-lock infusion system. The introducer is carefully withdrawn and the catheter maintained in place by pushing it forward with a nontoothed forceps, similar to the percutaneous insertion. The silicone catheter is connected again with the infusion system and the tip position adjusted if needed. The position of the silicone catheter is verified by X-rays. If the catheter tip is not in the correct position (i.e. in the portal vein), it is promptly removed and the percutaneous route is used.
Figure 1

The USVC introducers (8.9 and 11 cm), the silicone catheter and the easy-lock connection.

The USVC introducers (8.9 and 11 cm), the silicone catheter and the easy-lock connection. The catheter position is documented again 1 or 2 days later by echocardiography and eventually adjusted. Indeed, X-rays alone can be misleading for evaluation of catheter placement (4). Echocardiography is repeated 1 or 2 days before removal to exclude thrombosis. The patients with an umbilical line undergo abdominal echography before discharge in order to verify the portal and deep venous circulation. All newborn infants admitted in the NICU of Saint-Pierre University Hospital between January 2002 and December 2005 and who underwent central silicone catheterisation were included in this study. Data on catheter complications were retrospectively abstracted from patient records. The silicone catheters were preferentially inserted by umbilical route during the first 2 days of life using the technique described above. The percutaneous route was used if the attending physician was not familiar with the USVC technique, if the umbilical vein was not accessible anymore or if the USVC was incorrectly positioned (i.e. portal vein). The 339 patients were divided into four groups: those who had one catheter, whether transumbilical (group USVC, n = 161) or percutaneous (group PSVC, n = 125); those who had more than one catheter, an USVC followed by one or more PSVCs (group USVC–PSVC, n = 37) and those who had several PSVCs (group PSVC–PSVC, n = 16). We used χ2 test or Fisher's exact test to compare proportions. For numerical variables with a Gaussian distribution, comparisons between groups were performed using the Student's t-test. For those with a non-Gaussian distribution we used the Mann–Whitney U-test. For comparing rates of catheter related sepsis per 1000 catheter days, we used exact probabilities based on the binomial distributions. Patients who underwent USVC placement had birth weight ranging from 570 gm up to 3800 gm. Most of the USVCs were placed at birth, significantly earlier than the PSVCs (Table 1). A vast majority, 286 out of the 339 infants had one central venous line lasting their whole hospital stay. The frequencies of catheter complications are provided stratified by catheter rank (Table 2). None of the classically important catheter complications were significantly different among groups. The small group PSVC + PSVC showed more mechanical obstruction (p < 0.01).
Table 1

Clinical characteristics and catheter use of study infants

One catheterSeveral catheters


USVC n = 161PSVC n = 125USVC + PSVC n = 37PSVC + PSVC n = 16
Median (min–max) or N° (%)
Birthweight (g)1600 (700–3800)1640 (760–3630)1330 (570–2450)1175 (740–3500)
Gestational age (weeks)32 (25–41)32 (26–41)29 (25–34)28 (24–38)
Catheter inserted on first day of life132 (82.0%)68 (54.4%)**35 (94.6%)13 (81.2%)
Number of catheters
 232 (86.5%)14 (87.5%)
 3–45 (13.5%)2 (12.5%)
Duration of catheterization (days)
 Catheter 120 (2–48)19 (3–62)12 (1–43)19 (1–42)
 Catheter 2–421 (5–77)22 (4–54)
Elective withdrawal156 (96.9%)116 (92.8%)21 (56.8%)6 (37.5%)

p < 0.01 for comparison of PSVC (one catheter) with USVC (one catheter).

Table 2

Catheter complications

One catheterSeveral catheters


USVC n = 161PSVC n = 125USVC + PSVC n = 37PSVC + PSVC n = 16
N° (%) or rate per 1000 catheter days
Thrombosis
 First catheter3 (1.9%)0 (0.0%)1 (2.7%)0 (0.0%)
 Next catheter(s)0 (0.0%)0 (0.0%)
Mechanical obstruction
 First catheter0 (0.0%)1 (0.8%)6 (16.2%)9 (56.3%)**
 Next catheter(s)3 (8.1%)0 (0.0%)
Catheter-related sepsis
 First catheter1 (0.6%)3 (2.4%)4 (10.8%)2 (12.5%)
 Per 1000 catheter days0.311.167.606.99
 Next catheter(s)0 (0.0%)2 (12.5%)
 Per 1000 catheter days0.005.09
Probably related catheter sepsis
 First catheter1 (0.6%)5 (4.0%)7 (18.9%)0 (0.0%)
 Per 1000 catheter days0.311.9413.310.00
 Next catheter(s)2 (5.4%)0 (0.0%)
 Per 1000 catheter days2.130.00

p < 0.01 for comparison of PSVC + PSVC with USVC + PSVC.

Clinical characteristics and catheter use of study infants p < 0.01 for comparison of PSVC (one catheter) with USVC (one catheter). Catheter complications p < 0.01 for comparison of PSVC + PSVC with USVC + PSVC. This study is the first evaluation of long-term transumbilical venous access with silicone catheters in a large number of patients. Former reports examined a very limited number of cases and did not describe a specific device (5,6). This study is neither prospective nor randomised but describes a new technique that might have substantial advantages in the intravascular access problems of newborn and especially preterm infants. Our data demonstrate the feasibility to place USVC in all ranges of birth weight. Thrombosis occurred in four of the patients of the USVC group and not in the PSVC group. In 3 patients the routine echocardiography showed small asymptomatic thrombi at the catheter tip. They disappeared after thrombolytic treatment. One severe growth retarded patient showed partial portal vein thrombosis and portal hypertension diagnosed at the age of 3 months on abdominal echography. The patient completely recovered in follow-up. In our unit no heparin is routinely used for catheter maintenance. In a recent randomised controlled trial Shah et al. have shown that heparin infusion prolonged the duration of the peripherally inserted central venous catheter usability (7). This should be evaluated in the USVCs in further studies. No severe side effect like pericardial effusion or tamponade was observed in our series. Risk of malposition of the USVC in the portal vein is comparable to any venous umbilical catheterisation. Comparative data of venous catheters in published studies report absence of complications in 51% to 82% of the patients (2,8–12). In this study we observed no complications in 88% of the patients. In conclusion, we described the transumbilical use of a small-diameter silicone venous catheter. A specific introducer is needed to achieve placement. Indications for USVC placement are similar to PSVC. Complications in this study are comparable for USVC and PSVC. The advantages of USVC are an easy venous access, a sparing effect on peripheral veins and the baby's comfort. Further studies are needed to evaluate the use of USVC.
  11 in total

1.  Percutaneous central venous catheterization. Three years' experience in a neonatal intensive care unit.

Authors:  M K Chathas; J B Paton; D E Fisher
Journal:  Am J Dis Child       Date:  1990-11

2.  Echocardiographic evaluation of umbilical venous catheter placement.

Authors:  Anne Ades; Craig Sable; Susan Cummings; Russell Cross; Bruce Markle; Gerard Martin
Journal:  J Perinatol       Date:  2003-01       Impact factor: 2.521

3.  Percutaneous femoral venous catheterization in preterm neonates.

Authors:  F Abdulla; K A Dietrich; A K Pramanik
Journal:  J Pediatr       Date:  1990-11       Impact factor: 4.406

4.  A randomized, controlled trial of heparin versus placebo infusion to prolong the usability of peripherally placed percutaneous central venous catheters (PCVCs) in neonates: the HIP (Heparin Infusion for PCVC) study.

Authors:  Prakesh S Shah; Angela Kalyn; Prakash Satodia; Michael S Dunn; Boriana Parvez; Alan Daneman; Shia Salem; Phyllis Glanc; Arne Ohlsson; Vibhuti Shah
Journal:  Pediatrics       Date:  2007-01       Impact factor: 7.124

5.  Death as a complication of peripherally inserted central catheters in neonates.

Authors:  A M Nadroo; J Lin; R S Green; M S Magid; I R Holzman
Journal:  J Pediatr       Date:  2001-04       Impact factor: 4.406

6.  Accuracy of Doppler echocardiography for the diagnosis of thrombosis associated with umbilical venous catheters.

Authors:  Madan Roy; Sophronia Turner-Gomes; Gerald Gill; Clifton Way; John Mernagh; Barbara Schmidt
Journal:  J Pediatr       Date:  2002-01       Impact factor: 4.406

7.  Use of percutaneous silastic central venous catheters in neonates and the management of infectious complications.

Authors:  J F Klein; F Shahrivar
Journal:  Am J Perinatol       Date:  1992-07       Impact factor: 1.862

8.  Neonatal thrombosis: report of a prospective Canadian and international registry.

Authors:  B Schmidt; M Andrew
Journal:  Pediatrics       Date:  1995-11       Impact factor: 7.124

Review 9.  Percutaneous central venous catheters versus peripheral cannulae for delivery of parenteral nutrition in neonates.

Authors:  S B Ainsworth; L Clerihew; W McGuire
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

10.  Randomized, controlled trial of amoxicillin prophylaxis for prevention of catheter-related infections in newborn infants with central venous silicone elastomer catheters.

Authors:  K Harms; E Herting; M Kron; H Schiffmann; H Schulz-Ehlbeck
Journal:  J Pediatr       Date:  1995-10       Impact factor: 4.406

View more
  1 in total

1.  Skin-to-skin contact with an umbilical venous catheter: prospective evaluation in a level 3 unit.

Authors:  Zaoui-Grattepanche Catherine; Pindi Béatrice; Lapeyre Fabrice; Huart Claire; Duhamel Alain
Journal:  Eur J Pediatr       Date:  2015-11-19       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.